ArticleJournal of Korean medical science2025
Global, Regional, and National Burden of Pharyngeal Cancer and Projections to 2050 in 185 Countries: A Population-Based Systematic Analysis of GLOBOCAN 2022.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Navigating fatherhood and identity reconstruction among fathers with nasopharyngeal carcinoma: A qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Mechanism-guided radiosensitization strategies for nasopharyngeal carcinoma: Current evidence and translational perspectives (Review).Oncology letters · 2026Review
- Updating the standard model of care for oropharyngeal cancers-are we there yet?Translational cancer research · 2026Article
- Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy.Journal of the Egyptian National Cancer Institute · 2026Review
- Transcriptomic and experimental validation identify biomarkers and regulatory mechanisms associated with the aryl hydrocarbon receptor in nasopharyngeal carcinoma.Translational cancer research · 2026Article
- Geographic inequalities and gender-specific trends in oropharyngeal cancer mortality in Spain.Medicina oral, patologia oral y cirugia bucal · 2026Article
- Clinical Applications and Diagnostic Performance of Adjunctive Light-Based Optical Technologies in Oral Potentially Malignant Disorders and Squamous Cell Carcinoma: A Systematic Review.Journal of clinical medicine · 2026Review
- Oropharyngeal cancer mortality in the United States, 1999-2023: a surveillance analysis using CDC WONDER.Frontiers in oncology · 2026Article
- Article
- Diagnostic Value of Bronchoscopy in Detecting Laryngopharyngeal Disorders: Clinical Utility and Limitations.Medicina (Kaunas, Lithuania) · 2025Observational
- The global, regional, and national impact of laryngeal cancer from 1990 to 2021, along with forecasts for 2050: a comprehensive analysis for the Global Burden of Disease 2021 research.Frontiers in oncology · 2025Article
- Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance.BioImpacts : BI · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPharyngeal cancer has resulted in 3.23 million disability-adjusted life years as of 2019. Based on anatomical site, pharyngeal cancers are categorized into oropharyngeal cancers (OPCs), nasopharyngeal cancers (NPCs), and hypopharyngeal cancers (HPCs). The spatiotemporal distribution of each pharyngeal cancer is related to their respective risk factors.
methodsUsing the latest updated GLOBOCAN 2022 and Cancer Incidence in Five Continents database, global, regional, and national age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of pharyngeal cancer by anatomical site, as well as longitudinal trends since 1998 and future projections to 2050 were investigated across 185 countries and territories. We employed joinpoint regression to assess the average annual percentage change to quantify trends in the ASIR of pharyngeal cancer. We additionally present the mortality-to-incidence ratio as an indicator of disease fatality.
resultsIn 2022, an estimated 313,091 people were diagnosed with pharyngeal cancer (ASIR, 3.3 per 100,000 person-years) and 166,689 people died from pharyngeal cancer worldwide (ASMR, 1.7 per 100,000 person-years). Regardless of an individual's age and anatomical site, pharyngeal cancer exhibits significantly higher incidence and mortality rates in old males, and the highest number of cases and deaths occur in individuals aged 45-59 years in both sexes. The highest ASIRs per 100,000 person-years were found in Western Europe (2.6) and Northern America (2.6) for OPC, South-Eastern Asia (4.7) for NPCs, South Central Asia (2.1) and Eastern Europe (1.5) for HPC. ASMR per 100,000 person-years were higher for OPC and HPC in Eastern Europe (OPC, 1.1; HPC, 1.0), South Central Asia (OPC, 0.9; HPC, 0.8), and for NPC in South-Eastern Asia (3.1), and Micronesia (2.1). In most countries, the incidence of OPC either increased or remained at a similar level, and NPC remained stable in most countries and HPC decreased or remained unchanged in both sexes. If the ASIR and ASMR of 2022 are maintained, in 2050, the projected number of cases will increase by 63.64% for OPC, 46.40% for NPC, and 64.23% for HPC.
conclusionPharyngeal cancer represents a significant burden on global public health, with its disease burden varying across different demographic variables. These variations were closely associated with risk factors such as tobacco and alcohol use, high-risk human papillomavirus, and Epstein-Barr virus infections. To effectively manage the current and future global burden, tailored interventions aligned with unique epidemiological profiles of pharyngeal cancer in diverse populations are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.